The benefits of this formulation approach exist in concert with its challenges: because of the comparatively novel and bespoke nature of these drugs, additional formulation activity is often required to commercialize them. This investment frequently extends to equipment and process optimization, resulting in an array of unique technical challenges. At AbbVie, researchers have worked toward mitigating these issues by identifying a range of technology solutions, from tablet delamination to cross-contamination layers, layer separation, weight and depth control, and achieving acceptable yields and throughput.
Central to overcoming the challenges associated with bilayer tablet manufacturing is significant technical expertise, a strong commercial manufacturing network, and state-of-the-art equipment and processes. AbbVie is committed to investing in both new technologies and in customizing its equipment to streamline and optimize their manufacturing paradigms, enabling the successful development and commercialization of multiple bilayer tablet products.
Ensuring Optimal Bilayer Tablet Formulation
Bilayer tablets are produced by compressing two disparate formulations into a single solid oral tablet while maintaining a physical barrier between each formulation by layering one on top of the other. This enables the controlled delivery of either a single or multiple APIs within an individual tablet. This is particularly beneficial when one of the tablet layers provides an immediate release and the second layer a sustained release delivery.
Producing tablets that confer the desired release profile necessitates a focus on early optimization and subsequent scale-up. AbbVie possesses an extensive range of equipment to support both development and commercial-scale activities. For early development activity, AbbVie’s process blends in the 1kg range and scales up for any subsequent development and commercialization work. AbbVie typically produces 8,000 to 20,000 tablets per hour on its development presses, and would scale incrementally to approximately 600,000 tablets per hour at the commercial level.
For customers, the safety and quality compliance practices and standards employed by AbbVie are key. AbbVie consistently performs and delivers in this regard: its Lake County sites are regularly employed as a training site for the FDA, and its global quality system offers unparalleled flexibility for both product development and downstream applications. In addition, the company employs automated data acquisition and analysis capabilities, modern quality control and development laboratories, powder containment solutions, and on-site warehousing.
AbbVie’s Bilayer Tablet Manufacturing Capabilities
The timeframe in which AbbVie can scale a therapeutic to commercial production is highly product-dependent; generally, the process can take between 1.5 and 3 years. If stability testing and clinical are excluded, commercial manufacturing can likely be achieved within 12-18 months. AbbVie has extensive experience in the space, with four bilayers in development at its Ireland location alone, as well as a multitude of other solid oral dosage programs being run concurrently across its remaining five facility locations, which span both Europe and North America.
Despite their novel design, bilayer tablets are capable of being produced with the same cleaning standards as other tablet formulations. When manufactured in its commercial GMP facilities, AbbVie’s contract customers’ products adhere to the AbbVie cleaning standards. This includes cleaning recipe and method development, cleaning verification, and test method transfer and validation.
As a leading pharmaceutical developer and manufacturer, AbbVie Contract Manufacturing has experience with bilayer manufacturing for clients at its high-technology solid dose manufacturing sites in Ireland, Germany, Puerto Rico and Illinois at AbbVie to discuss your bilayer manufacturing needs at www.abbviecontractmfg.com or at 1-847-457-0727.